Ambulatory antimicrobial therapy for hematologic malignancies

ONCOLOGY

Volumn 14, Issue 8 SUPPL. 6, 2000, Pages 17-22

  Rolston, Kenneth V I ^a   Talcott, James A ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

BLOOD DISEASE; CROSS INFECTION; DRUG COMBINATION; FEVER; HUMAN; INFECTION; METHODOLOGY; NEUTROPENIA; OUTPATIENT; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK MANAGEMENT;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG THERAPY, COMBINATION; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; INFECTION; NEUTROPENIA; OUTPATIENTS; PRACTICE GUIDELINES; QUALITY OF LIFE; RISK MANAGEMENT;

EID: 0034240906     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Freifeld AG, Pizzo PA: The outpatient management of febrile neutropenia in cancer patients. Oncology 10:599-612, 1996.
2. Rolston KV: New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29:515-521, 1999.
3. Talcott JA, Finberg R, Mayer RJ, et al: The medical course of cancer patients with fever and neutropenia. Arch Inlern filed 148:2561-2568, 1988.
4. Talcott JA, Siegel RD, Finberg R, et al: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322, 1992.
5. Talcott JA, Whalen A, Clark J, et al: Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107-114, 1994.